Shares of BioNTech ( NASDAQ:BNTX) were falling 7.3% as of 11:24 a.m. EDT on Tuesday. The German biotech didn't announce any news. The most likely reason behind the decline was that Sanofi ( NASDAQ:SNY) is expanding its collaboration with Translate Bio ( NASDAQ:TBIO) to develop messenger RNA (mRNA) vaccines.
Should you buy bntx stock?
Overshadowed a bit by its much larger vaccine partner Pfizer, BioNTech is perhaps the most under-the-radar vaccine stock play, if there is such a thing. Only 10.5% of BNTX stock is held by institutions, and yet shares still more than doubled in the last year.
Why are Moderna shares down?
With the omicron variant proving to be highly infectious, there is a view among the scientific community, herd immunity could soon be reached, bringing the pandemic to an end. (Get Free Alerts for MRNA) shares were down 2.36% at $205.20. was slipping 2.01% at $198.90.
Why is Biotech stock down?
Nearly 400 publicly traded biotech companies have lost 40% or more of their value in just the past six months. The market's irrational behavior toward all things biotech, however, isn't necessarily a bad thing for patient investors.
Why are biotech stocks dropping?
With the biggest decline in more than two months, the shares of the Cambridge, Massachusetts-based biotech reached a 10-week low on above-average volume. The recent investor sentiment is not in ...
See more
Why is BioNTech stock price dropping?
The good news regarding the drop in COVID-19 cases around the country is being perceived as bad news for BioNTech, whose Comirnaty COVID-19 vaccine it developed with Pfizer has sent the company to record revenue and profits in 2021.
Is BNTX stock a good buy?
BioNTech has had an excellent 2021. 2022 and beyond will most likely not be this good, however. The company is very reliant on its COVID vax business today, but BNTX has some attractive pipeline candidates. For risk-hungry investors, BNTX might have value today.
Is BioNTech stock expected to rise?
Stock Price Forecast The 12 analysts offering 12-month price forecasts for BioNTech SE have a median target of 246.41, with a high estimate of 356.61 and a low estimate of 170.87. The median estimate represents a +47.58% increase from the last price of 166.97.
Is it worth investing in BioNTech?
If you're an investor who typically invests in biotech stocks and is comfortable with the risks that they entail, I'd say that buying BioNTech today isn't a terrible decision. In the long run, its research and development activity should pay off, and it's in no great hurry for its pipeline projects to bear fruit.
Is BioNTech a hold?
BioNTech has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.
Is BioNTech a buy Zacks?
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return4Sell5.79%5Strong Sell2.83%S&P50011.24%3 more rows
Will BNTX stock go up tomorrow?
Tomorrow's movement Prediction of Biontech Se ADR BNTX as on 13 May 2022 appears undecisive. It can be Bearish or Bullish....Munafa value: 56 as on 13 Fri May 2022.Upside target168.5Upside target160.17Downside target155.34Downside target152.96Downside target151.845 more rows
What is the target price for Pfizer?
Stock Price TargetsHigh$75.00Median$55.00Low$49.00Average$57.61Current Price$51.78
What is the target price for Moderna?
Stock Price TargetHigh$506.00Low$70.00Average$217.62Current Price$134.04
Is BioNTech a buy right now?
13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 7 hold r...
When is BioNTech's next earnings date?
BioNTech is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for BioNTech .
How were BioNTech's earnings last quarter?
BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings results on Monday, May, 9th. The company reported $15.98 earnings per share for the quarter...
How often does BioNTech pay dividends? What is the dividend yield for BioNTech?
BioNTech declared a -- dividend on Thursday, April 28th. Investors of record on Friday, June 3rd will be paid a dividend of $1.5342 per share on Fr...
What price target have analysts set for BNTX?
13 brokers have issued 12 month price targets for BioNTech's shares. Their forecasts range from $146.00 to $359.00. On average, they anticipate Bio...
Who are BioNTech's key executives?
BioNTech's management team includes the following people: Prof. Ugur Sahin M.D. , Co-Founder, CEO & Chair of the Management Board (Age 56, Pay $...
What is Ugur Sahin's approval rating as BioNTech's CEO?
10 employees have rated BioNTech CEO Ugur Sahin on Glassdoor.com . Ugur Sahin has an approval rating of 89% among BioNTech's employees.
Who are some of BioNTech's key competitors?
Some companies that are related to BioNTech include Amgen (AMGN) , Gilead Sciences (GILD) , Moderna (MRNA) , Biogen (BIIB) , Seagen (SGEN) ,...
What other stocks do shareholders of BioNTech own?
Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA) , Pfizer (P...
About BioNTech
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
Headlines
BioNTech Vs. Moderna Updated: Valuations Will Suffer Further In Post-Pandemic Climate - Seeking Alpha
BioNTech (NASDAQ:BNTX) Frequently Asked Questions
13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BioNTech stock.
What happened
Shares of several top COVID-19 vaccine makers were sinking on Tuesday. Pfizer (NYSE: PFE) stock was down 2.7% as of 11:09 a.m. EDT. Shares of Pfizer's partner, BioNTech (NASDAQ: BNTX), were falling 7%. Moderna (NASDAQ: MRNA) stock was tumbling 5.4%. Novavax (NASDAQ: NVAX) was the biggest loser with its shares declining 8.1%.
So what
It's really not all that surprising that these stocks would give up much of the gains from Monday. FDA approval for the Pfizer-BioNTech vaccine was fully expected.
Now what
Pfizer, BioNTech, and Moderna hope to win EUAs for their vaccines in younger children within the next few months. The companies also will pursue full FDA approvals in these age groups. Novavax plans to file for EUA of its COVID-19 vaccine in the fourth quarter, with submissions in the U.K. and Europe coming even sooner.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.